Biotech Startups

AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.

1 investor

Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD. It serves patients with chronic and infectious respiratory conditions in the biotechnology and pharmaceutical space.

1 investor

Alvogen is a pharmaceutical company committed to making high-quality medicines more accessible through a focus on best people, portfolio, service, quality, and cost efficiency. The company serves customers globally in the pharmaceutical industry.

1 investor

Alyssum is a biotechnology company developing novel therapeutic drugs, with expertise in protein engineering, oncology, and clinical development. Its leadership includes veterans of multiple FDA-approved medicines and accelerated approvals.

1 investor

Alzprotect is a biotech company developing therapeutic candidates for neurodegenerative diseases, including tauopathies such as Progressive Supranuclear Palsy (PSP) and Alzheimer's disease. Its lead drug candidate targets multiple markers of neurodegeneration including amyloid beta peptide, Tau protein, neuroinflammation, and oxidative stress.

1 investor

Amadix develops blood-based diagnostic tests for early cancer detection before symptoms appear. The company focuses on non-invasive liquid biopsy technology to identify tumors years earlier than traditional methods.

1 investor

Amalgent is a clinical-stage pain management company developing oral combination drug therapeutics that repurpose existing medications to improve the safety of severe pain treatment. It initially targets the US market.

1 investor

Amaros builds AmarosEngine, a precision intelligence platform that integrates ophthalmology clinics' EHR, practice management, and imaging systems to unify ophthalmic data and generate real-world evidence and insights. It serves CROs, pharma, biotech, and eye-care clinics across the ophthalmic ecosystem for clinical trials, point-of-care treatment, and commercial growth, primarily in the United States with global expansion.

1 investor

Amaryllis Tx develops tissue-targeted drug delivery by mapping tissue-specific glycan signatures and designing peptides that recognize them, using in silico and in vivo screening. Its lead peptide enables subcutaneously injected payloads such as antibodies, mRNA, ASO, and siRNA to cross the blood-brain barrier, initially targeting the brain.

1 investor

Amayu operates a platform in Germany that connects patients with ketamine therapy for psychiatric and chronic conditions, combining medical ketamine treatments delivered by independent partner physicians with accompanying psychological support. It coordinates in-practice sessions and online video consultations for conditions such as depression, anxiety, trauma, OCD, chronic pain, and addiction, currently offering treatment in Berlin with planned expansion to other German cities.

1 investor

Amazentis is a Swiss longevity-biotech company that developed Mitopure, a proprietary high-purity form of the postbiotic Urolithin A shown in human trials to support mitochondrial health via mitophagy. It brings the molecule to consumers through its Timeline brand of supplements and skincare, and partners with companies including Nestlé Health Science and L'Oréal.

1 investor

AmbiMass Kft. is a Hungarian company specializing in mass spectrometry, including precise measurement, sample preparation, and data evaluation. It also integrates laser optical systems into mass spectrometry applications and develops standalone analytical systems, drawing on a multidisciplinary team of engineers, software developers, chemists, and biologists.

1 investor

Amelieff provides bioinformatics support to research and development clients through IT systems, data analysis, training programs, and consulting. It also offers study sessions, seminars, and on-demand educational videos on bioinformatics.

1 investor

American Gene Technologies develops gene therapy treatments for serious diseases including HIV, phenylketonuria, and liver cancer, using a proprietary platform approach designed to accelerate drug development and reduce costs.

1 investor

Ametris provides sensor-based digital measures and digital endpoints for clinical trials, capturing data from wearable sensors and real-world patient insights. Now part of Signant Health, it supports clinical trial sponsors running decentralized, hybrid, and traditional studies alongside electronic Clinical Outcome Assessment (eCOA) capabilities.

1 investor

Amino Labs produces hands-on biotechnology experiment kits designed to teach genetic engineering and bacterial transformation to beginners in educational and hobbyist settings. The kits enable students and DIY biology enthusiasts to perform genetic engineering experiments on bacteria and learn foundational concepts in biotechnology.

1 investor

Amino Analytica designs rapid molecular diagnostic tests for emerging infectious diseases and biological threats, developed in weeks rather than the traditional 12+ months. The company combines point-of-care diagnostics technology with AI-driven bionanotechnology to enable earlier detection and faster pandemic response.

1 investor

Amino Collective is an early-stage venture capital firm that invests in health and biotechnology companies at the pre-seed and seed stages. The firm operates with a concentrated investment approach, typically backing a small number of companies annually.

1 investor

AMLo Biosciences develops prognostic and companion diagnostic tests for cancer patients, initially focusing on melanoma and oropharyngeal squamous cell carcinoma. The company translates cancer biomarker research into tests designed to stratify patient risk and optimize treatment allocation.

1 investor

Amnova Biotech develops injectable therapies derived from amniotic biomaterials to promote heart regeneration following ischemic injury. The company targets cardiac regenerative medicine and is advancing its lead therapies from preclinical validation toward clinical application.

1 investor

Amoy Diagnostics develops molecular diagnostic test kits for cancer detection, including PCR, IHC, FISH, and next-generation sequencing products that detect gene mutations such as PIK3CA, KRAS, NRAS, BRAF, and IDH1, as well as microsatellite instability. Its products serve clinical and oncology diagnostics and include related nucleic acid extraction reagents and instruments.

1 investor

Amphastar Pharmaceuticals manufactures and distributes generic and branded pharmaceutical products, including injectable medications, inhalation aerosols, and emergency treatments for medical professionals and patients in the United States.

1 investor

Amplicore Pharma develops an injectable pharmaceutical formulation targeting musculoskeletal disorders, particularly osteoarthritis, designed to slow cartilage degeneration and reduce symptoms as an alternative to joint replacement surgery.

1 investor

Amplifier Therapeutics is a biotech company developing an AMPK activator drug intended to restore cellular metabolism and treat or prevent chronic, aging-related diseases. It is presented as a subsidiary ("PipeCo") of Cambrian Bio.

1 investor